{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T14:27:33Z","timestamp":1793543253110,"version":"4.5.0"},"reference-count":46,"publisher":"The Journal of Rheumatology","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2026,6,3]]},"published-print":{"date-parts":[[2026,11]]},"abstract":"\n Objective<\/jats:title>\n To assess the 3-year effect of bimekizumab on health status, work productivity, and productivity-related costs in patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n BE MOBILE 1 (\n ClinicalTrials.gov<\/jats:ext-link>\n :\n NCT03928704<\/jats:ext-link>\n ) and BE MOBILE 2 (\n NCT03928743<\/jats:ext-link>\n ), phase III trials in axSpA, and BE OPTIMAL (\n NCT03895203<\/jats:ext-link>\n ) and BE COMPLETE (\n NCT03896581<\/jats:ext-link>\n ), phase III trials in PsA, evaluated subcutaneous bimekizumab 160 mg every 4 weeks. Patients who completed these studies were eligible to enter the open-label extension studies BE MOVING (\n NCT04436640<\/jats:ext-link>\n ; axSpA) or BE VITAL (\n NCT04009499<\/jats:ext-link>\n ; PsA). Outcomes are reported by indication for observed cases among patients originally randomized to placebo or bimekizumab through year 3. These included changes in health status (EQ-5D-3L and the EQ visual analog scale [VAS; 0-100]), work productivity (Work Productivity and Activity Impairment Questionnaire\u2013Specific Health Problem v2.0 [WPAI-SHP]), and annualized productivity cost savings associated with improvements in work impairment.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 586 patients with axSpA and 1112 patients with PsA, mean EQ VAS scores improved by 20.2-21.3 points in axSpA and 17.1-17.3 points in PsA from baseline to year 3. At year 3, most patients reported clinically meaningful improvements in work impairment (axSpA: 74.2-81.1%; PsA: 71.2-71.3%) and achieved an acceptable work state, defined by WPAI-SHP presenteeism < 40% (axSpA: 83.7-84.2%; PsA: 84.1-87.2%). In the US, productivity cost savings (in US dollars) were sustained to year 3 ($22,012.14-22,549.32 in axSpA, and $13,327.60-16,428.25 in PsA); similar trends were observed in Europe and Japan.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Bimekizumab demonstrated sustained improvements in health status and work productivity to year 3 across axSpA and PsA. Health status was comparable to population norms at year 3. Productivity cost savings from reduced work impairment were observed, reflecting a reduced economic and social burden of axSpA and PsA.<\/jats:p>\n <\/jats:sec>","DOI":"10.3899\/jrheum.2026-0104","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:35:25Z","timestamp":1782909325000},"page":"1207-1220","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis"],"prefix":"10.3899","volume":"53","author":[{"given":"Elena","family":"Nikiphorou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-4125","authenticated-orcid":false,"given":"William","family":"Tillett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6253-1515","authenticated-orcid":false,"given":"Maureen","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-310X","authenticated-orcid":false,"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2160-1481","authenticated-orcid":false,"given":"Mark","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-5328","authenticated-orcid":false,"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-7972","authenticated-orcid":false,"given":"Pedro M.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-548X","authenticated-orcid":false,"given":"Martin","family":"Rudwaleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-6354","authenticated-orcid":false,"given":"Maarten","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"de la Loge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"M\u00f8rup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0682-9533","authenticated-orcid":false,"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-0845","authenticated-orcid":false,"given":"Jessica","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2026110105301034000_53.11.1207.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2026110105301034000_53.11.1207.2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003063"},{"key":"2026110105301034000_53.11.1207.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221035"},{"key":"2026110105301034000_53.11.1207.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"2026110105301034000_53.11.1207.5","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-00172-9"},{"key":"2026110105301034000_53.11.1207.6","first-page":"997","article-title":"Health care utilization and costs associated with functional status in patients with psoriatic arthritis","volume":"28","author":"Ogdie","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"2026110105301034000_53.11.1207.7","first-page":"1008","article-title":"Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis","volume":"28","author":"Ogdie","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"2026110105301034000_53.11.1207.8","doi-asserted-by":"crossref","unstructured":"Devlin N , Pickard S , Busschbach J. The development of the EQ-5D-5L and its value sets. Value sets for EQ-5D-5L: a compendium, comparative review & user guide. Cham: Springer; 2022.","DOI":"10.1007\/978-3-030-89289-0_1"},{"key":"2026110105301034000_53.11.1207.9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/rheumatology\/keu264","article-title":"Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study","volume":"54","author":"Tillett","year":"2014","journal-title":"Rheumatology"},{"key":"2026110105301034000_53.11.1207.10","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003468"},{"key":"2026110105301034000_53.11.1207.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110405"},{"key":"2026110105301034000_53.11.1207.12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004877"},{"key":"2026110105301034000_53.11.1207.13","first-page":"S136","article-title":"A systematic literature review of the economic impact of ankylosing spondylitis","volume":"30","author":"Palla","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2026110105301034000_53.11.1207.14","doi-asserted-by":"crossref","first-page":"e0126105","DOI":"10.1371\/journal.pone.0126105","article-title":"The cost of ankylosing spondylitis in the UK using linked routine and patient-reported survey data","volume":"10","author":"Cooksey","year":"2015","journal-title":"PLoS One"},{"key":"2026110105301034000_53.11.1207.15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11926-020-00932-5","article-title":"Work disability in axial spondyloarthritis","volume":"22","author":"Nikiphorou","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"2026110105301034000_53.11.1207.16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894"},{"key":"2026110105301034000_53.11.1207.17","doi-asserted-by":"crossref","first-page":"keag118","DOI":"10.1093\/rheumatology\/keag118","article-title":"Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies","volume":"65","author":"Gossec","year":"2026","journal-title":"Rheumatology"},{"key":"2026110105301034000_53.11.1207.18","doi-asserted-by":"crossref","unstructured":"Baraliakos X , Deodhar A , van der Heijde D , . Bimekizumab long-term safety and efficacy across the spectrum of axial spondyloarthritis over 3 years: results from two phase 3 studies. J Rheumatol 2026 June 15 (Epub ahead of print).","DOI":"10.3899\/jrheum.2026-0113"},{"key":"2026110105301034000_53.11.1207.19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004202"},{"key":"2026110105301034000_53.11.1207.20","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004464"},{"key":"2026110105301034000_53.11.1207.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-0923"},{"key":"2026110105301034000_53.11.1207.22","doi-asserted-by":"crossref","first-page":"rkag009","DOI":"10.1093\/rap\/rkag009","article-title":"Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies","volume":"10","author":"Tillett","year":"2026","journal-title":"Rheumatol Adv Pract"},{"key":"2026110105301034000_53.11.1207.23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-006013"},{"key":"2026110105301034000_53.11.1207.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224803"},{"key":"2026110105301034000_53.11.1207.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02302-9"},{"key":"2026110105301034000_53.11.1207.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02303-0"},{"key":"2026110105301034000_53.11.1207.27","unstructured":"EuroQol . User guides. [Internet. Accessed on June 29, 2026.] Available from: https:\/\/euroqol.org\/information-and-support\/documentation\/user-guides\/"},{"key":"2026110105301034000_53.11.1207.28","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/02692163211058596","article-title":"Patient perspectives on states worse than death: a qualitative study with implications for patient-centered outcomes and values elicitation","volume":"36","author":"Auriemma","year":"2022","journal-title":"Palliat Med"},{"key":"2026110105301034000_53.11.1207.29","unstructured":"Reilly Associates . WPAI:SHP, V2.0. [Internet. Accessed June 29, 2026.] Available from: www.reillyassociates.net\/WPAI_SHP.html"},{"key":"2026110105301034000_53.11.1207.30","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-0155-5"},{"key":"2026110105301034000_53.11.1207.31","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/rheumatology\/keae033","article-title":"Thresholds for unacceptable work state in radiographic axial spondyloarthritis of four presenteeism and two clinical outcome measurement instruments","volume":"64","author":"Capelusnik","year":"2024","journal-title":"Rheumatology"},{"key":"2026110105301034000_53.11.1207.32","unstructured":"OECD . Average annual wages. [Internet. Accessed on June 29, 2026.] Available from: https:\/\/www.oecd.org\/en\/data\/indicators\/average-annual-wages.html"},{"key":"2026110105301034000_53.11.1207.33","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40744-024-00642-9","article-title":"Work productivity and general health through 2 years of guselkumab treatment in a phase 3 randomized trial of patients with active psoriatic arthritis","volume":"11","author":"Curtis","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026110105301034000_53.11.1207.34","unstructured":"OECD . Comparable estimates of average wages per full-time equivalent employee. [Internet. Accessed June 29, 2026.] Available from: https:\/\/www.oecd.org\/content\/dam\/oecd\/en\/publications\/support-materials\/2023\/07\/oecd-employment-outlook-2023_904bcef3\/average_wages.pdf"},{"key":"2026110105301034000_53.11.1207.35","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-018-0955-5"},{"key":"2026110105301034000_53.11.1207.36","doi-asserted-by":"crossref","unstructured":"Szende A , Janssen B , Cabases J. Self-reported population health: an international perspective based on EQ-5D. Dordrecht, Nuevo Le\u00f3n, Mexico: Springer; 2014.","DOI":"10.1007\/978-94-007-7596-1"},{"key":"2026110105301034000_53.11.1207.37","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s40744-024-00708-8","article-title":"Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies","volume":"11","author":"Mease","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026110105301034000_53.11.1207.38","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1093\/rheumatology\/keaf009","article-title":"Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies","volume":"64","author":"Baraliakos","year":"2025","journal-title":"Rheumatology"},{"key":"2026110105301034000_53.11.1207.39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae277"},{"key":"2026110105301034000_53.11.1207.40","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1534-z"},{"key":"2026110105301034000_53.11.1207.41","unstructured":"Waddell G , Burton A. Is work good for your health and well-being? London: TSO; 2006."},{"key":"2026110105301034000_53.11.1207.42","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40265-025-02192-y","article-title":"Navigating psoriatic arthritis: treatment pathways and patient-specific strategies for improved outcomes","volume":"85","author":"Queiro","year":"2025","journal-title":"Drugs"},{"key":"2026110105301034000_53.11.1207.43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213590"},{"key":"2026110105301034000_53.11.1207.44","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03282-0"},{"key":"2026110105301034000_53.11.1207.45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13075-023-03058-y","article-title":"Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study","volume":"25","author":"Gossec","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2026110105301034000_53.11.1207.46","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15237"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2026-0104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T13:30:38Z","timestamp":1793539838000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2026-0104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11,1]]},"published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.3899\/jrheum.2026-0104"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2026-0104","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}